Back to top
more

Aveanna Healthcare (AVAH)

(Real Time Quote from BATS)

$3.86 USD

3.86
132,605

+0.04 (1.05%)

Updated Aug 5, 2025 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Equity Research

Fast-paced Momentum Stock Aveanna (AVAH) Is Still Trading at a Bargain

by Zacks Equity Research

Aveanna (AVAH) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Option Care Health, Inc. (OPCH) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Option Care (OPCH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Harshit Gupta headshot

AVAH Surges 45% in Five Days: How to Play the Stock After Earnings?

by Harshit Gupta

AVAH trades at a discount despite growth in payor deals & services. With solid fundamentals amid labor shortages, is it a buy or hold after earnings?

Zacks Equity Research

Here's Why you Should Retain Nevro Stock in Your Portfolio Now

by Zacks Equity Research

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

Zacks Equity Research

Aveanna (AVAH) Surges 6.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Aveanna (AVAH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Here's Why You Should Retain Surmodics Stock in Your Portfolio Now

by Zacks Equity Research

SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.

Zacks Equity Research

Will ISRG Stock Drop Continue After da Vinci 5 Recall?

by Zacks Equity Research

Intuitive Surgical faces a Class 2 recall for its da Vinci 5 system due to a pedal issue. Will this affect its 2025 rollout? Investors watch closely!

Zacks Equity Research

Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year?

by Zacks Equity Research

Here is how Aveanna Healthcare (AVAH) and Equillium, Inc. (EQ) have performed compared to their sector so far this year.

Zacks Equity Research

Aveanna (AVAH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Aveanna (AVAH) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio

by Zacks Equity Research

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Indrajit Bandyopadhyay headshot

Here's Why You Should Add Cencora Stock to Your Portfolio Now

by Indrajit Bandyopadhyay

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock

Zacks Equity Research

CAH Stock Up Nearly 7% This Year: Is Now the Time to Buy?

by Zacks Equity Research

CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.

Kaibalya Pravo Dey headshot

3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025

by Kaibalya Pravo Dey

GILD, OPCH and AVAH demonstrate resilience with impressive earnings surprise history.

Zacks Equity Research

VEEV Stock Up as Q4 Earnings & Revenues Beat Estimates, Margin Rise

by Zacks Equity Research

Veeva Systems' fiscal fourth-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.

Zacks Equity Research

Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down

by Zacks Equity Research

NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.

Zacks Equity Research

STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval

by Zacks Equity Research

Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.

Zacks Equity Research

Owens & Minor Shares Surge 39% on Earnings Beat and Growth Plans

by Zacks Equity Research

OMI's shares witnessed a massive uptick after the company posted stronger-than-expected Q4 earnings. Its strategic focus on Patient Direct and the Rotech acquisition indicates long-term shareholder value.

Zacks Equity Research

GEHC Stock May Rise on Freelium Magnet Launch, Boosts MR Access

by Zacks Equity Research

GE HealthCare unveils Freelium, a next-gen sealed magnet platform designed to revolutionize MR imaging with minimal helium usage.

Zacks Equity Research

GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?

by Zacks Equity Research

Glaukos reported robust fourth-quarter revenues, but shares plunged 24.8% post-earnings. Can expanding iDose TR adoption and global growth offset competitive pressures and valuation concerns in 2025?

Zacks Equity Research

CLOV Q4 Earnings Beat Estimates, Sales Miss, Membership Rises

by Zacks Equity Research

Clover Health's fourth-quarter 2024 results continue to benefit from the strength of its strong member retention. Strong revenue outlook bodes well.

Zacks Equity Research

RadNet (RDNT) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

RadNet (RDNT) delivered earnings and revenue surprises of 46.67% and 4.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can ITGR Stock's Growth Drivers Offset Rising Risks in 2025?

by Zacks Equity Research

Integer Holdings projects 8-10% sales growth in 2025, driven by acquisitions and high-demand medical technologies. But, can it overcome tariff and margin pressures?